Key clinical point: Benefits in lumbar spine bone mineral density and bone strength continue after switch from romosozumab to alendronate.
Major finding: The romosozumab group had significant improvements in areal bone mineral density percentage changes, compared with the alendronate group, which persisted until 24 months (P less than .001 for all).
Study details: An imaging substudy of 90 patients in the ARCH study who underwent quantitative CT to measure lumbar spine bone mineral density and finite element analysis to measure lumbar spine bone strength.
Disclosures: Amgen, UCB Pharma, and Astellas Pharma funded the study in part. Amgen and UCB Pharma assisted in the preparation of Dr. Brown’s presentation at ASBMR 2019, including funding costs associated with its development. Dr. Brown and the other coauthors reported relationships with Amgen, UCB Pharma, and other companies in the form of consultancies, grants and research support, speaker’s bureau appointments, paid employment, and stock options.
Brown JP et al. ASBMR 2019, Abstract 1050.